By Bachem AG
To get in touch with Bachem AG, simply fill out the form below.
Subscribe to Supplier
Bachem webinar on binary solvents for greener SPPS peptide synthesis
Bubendorf, Switzerland: –Peptide technology specialist Bachem is collaborating with global pharmaceutical leader Novo Nordisk to co-host a seminar on greening solid-phase peptide synthesis).
The webinar ‘No More DMF: Greener Solid-Phase Peptide Synthesis With Binary Solvents’ shows how the two partners worked together to identify environmentally benign and less hazardous alternatives to N.N-dimethylformamide (DMF) in solid-phase peptide synthesis (SPPS), using mixtures of two green solvents (binary solvents).
Predicting solvent behavior
The one-hour webinar will take place on Thursday , May 12, 2022, commencing at 1730 hrs CEST (UTC +2) and is free to register via the Bachem 360 zone (see Resources).
It will show how the polarity and viscosity profiles of binary solvents can be used to predict their utility for producing different peptides by SPPS. Furthermore, variation of the composition of the binary solvent mixture provides new opportunities to calibrate solvents to optimize individual steps in SPPS.
The session will feature two main speakers:
- Sandip Jadhav, Bachem R&D Project Chemist R&D at Bachem with particular expertise in utility of peptides in tissue engineering and in peptide modulators for aggregation-prone proteins
- Mirko Lotz, Bachem Group Leader for Science Marketing with focus on greener manufacturing of peptides and oligonucleotides
Question and Answer session
The main presentations will be followed by a Q&A session that will also include contributions from Dr. Daniel Sejer Pedersen, Senior Development Scientist in CMC Chemical Development at Novo Nordisk focusing on GMP manufacturing, and Dr. Carolin Lechner, Director of the R&D III department at Bachem, focusing on early phase peptide NCE development as well as GMP manufacturing of late phase peptide APIs.
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. With over 50 years of experience and expertise, Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange. For further information, see www.bachem.com.
Click on Bachem webinar ‘No more DMF: Greener solid-phase peptide synthesis with binary solvents’ to register for the event.
Subscribe to Bachems Newsletter to receive the latest updates.